MARKET

QTNT

QTNT

Quotient
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.900
+0.060
+2.11%
After Hours: 2.900 0 0.00% 16:11 09/17 EDT
OPEN
2.850
PREV CLOSE
2.840
HIGH
3.039
LOW
2.790
VOLUME
2.53M
TURNOVER
--
52 WEEK HIGH
7.59
52 WEEK LOW
2.625
MARKET CAP
294.61M
P/E (TTM)
-2.6537
1D
5D
1M
3M
1Y
5Y
Quotient Wins $3.7M Veterans Affairs Contract
https://sam.gov/opp/96f989cce2614269929b7324ce9ebdd9/view  
  · 6h ago
3 Strong Buy Stocks That Can More Than Double According to Finscreener’s Stock Screener
The advent of stock screeners in the past decade has made it easier for retail investors to invest in the equity markets. Now, even a newbie investor with little knowledge about stock market investing can access this asset class due to easy-to-use financia...
Vehement Media · 3d ago
Quotient Limited Announces Christian Albrich as Chief People Officer
JERSEY, Channel Islands, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that Christian Albrich has been appointed as...
GlobeNewswire · 09/01 12:21
Even after rising 13% this past week, Quotient (NASDAQ:QTNT) shareholders are still down 59% over the past three years
Quotient Limited ( NASDAQ:QTNT ) shareholders should be happy to see the share price up 13% in the last week. But that...
Simply Wall St. · 08/26 14:06
Pura Vida Investments, Llc Buys ATAI Life Sciences NV, Apria Inc, Agilon Health Inc, Sells , ...
GuruFocus News · 08/18 19:38
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Quotient Limited Announces Departure of Chief Commercial Officer, Jeremy Stackawitz
JERSEY, Channel Islands, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), announced that Jeremy Stackawitz has notified the Company that he is resigning from his position as Chief Comme...
GlobeNewswire · 08/11 11:45
Goldman Sachs Maintains Neutral on Quotient, Lowers Price Target to $4.5
Goldman Sachs maintains Quotient (NASDAQ:QTNT) with a Neutral and lowers the price target from $5 to $4.5.
Benzinga · 08/06 12:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QTNT. Analyze the recent business situations of Quotient through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QTNT stock price target is 10.25 with a high estimate of 14.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 130
Institutional Holdings: 102.04M
% Owned: 100.44%
Shares Outstanding: 101.59M
TypeInstitutionsShares
Increased
30
4.03M
New
10
152.05K
Decreased
40
3.37M
Sold Out
9
195.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Heino.N.F.M von Prondzynski
Chief Executive Officer
Manuel Mendez
Chief Financial Officer/IR Contact Officer
Peter Buhler
Chief Human Resource Officer
Christian Albrich
Chief Technology Officer
Michael Hausmann
Other
Jeremy Stackawitz
Independent Director
Isabelle Buckle
Independent Director
Frederick Hallsworth
Independent Director
Catherine Larue
Independent Director
Brian McDonough
Independent Director
Zubeen Shroff
Independent Director
John Wilkerson
No Data
  • All
  • Financials
  • Insiders
More
About QTNT
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Webull offers kinds of Quotient Ltd stock information, including NASDAQ:QTNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QTNT stock methods without spending real money on the virtual paper trading platform.